Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial
暂无分享,去创建一个
Henry C Kitchener | Bart Spiessens | Frank Struyf | Cosette M Wheeler | Jorge Salmerón | Jorma Paavonen | Diane M Harper | Gary Dubin | C. Wheeler | F. X. Bosch | H. Kitchener | M. Lehtinen | D. Harper | X. Castellsagué | J. Hedrick | S. Chow | F. Bosch | D. Apter | J. Paavonen | D. Jenkins | P. Naud | J. Salmerón | N. S. Carvalho | S. Skinner | U. Jaisamrarn | G. Limson | M. Dionne | Wim Quint | B. Spiessens | Pascal Peeters | F. Struyf | S. Wieting | G. Dubin | F Xavier Bosch | Song-Nan Chow | Paulo Naud | David Jenkins | Wim Quint | Pascal Peeters | Xavier Castellsague | Dan L Apter | Newton S de Carvalho | S Rachel Skinner | James A Hedrick | Unnop Jaisamrarn | Genara AM Limson | Marc Dionne | Susan L Wieting | Matti O Lehtinen | N. D. de Carvalho | N. Carvalho | Henry C Kitchener | S. R. Skinner | F. Bosch | F Xavier Bosch | Cosette M Wheeler | Dan L Apter | Newton S de Carvalho | S Rachel Skinner | James A Hedrick | Genara AM Limson | Susan L Wieting | Matti O Lehtinen | W. Quint | Genara Limson | C. Wheeler
[1] Daron G Ferris,et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.
[2] A. Tsiatis,et al. Approximately optimal one-parameter boundaries for group sequential trials. , 1987, Biometrics.
[3] M. Stanley,et al. Prophylactic HPV vaccines: prospects for eliminating ano-genital cancer , 2007, British Journal of Cancer.
[4] S. Pagliusi,et al. Efficacy and other milestones for human papillomavirus vaccine introduction. , 2004, Vaccine.
[5] F. X. Bosch,et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. , 2003, The New England journal of medicine.
[6] Claude Fauquet,et al. Classification of papillomaviruses. , 2004, Virology.
[7] C. Wheeler,et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.
[8] K. Herck,et al. Prevention of hepatitis A by Havrix™: a review , 2005 .
[9] F. Wiklund,et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. , 1999, The New England journal of medicine.
[10] Helen Trottier,et al. The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.
[11] H. Hoyer,et al. Cumulative 5‐year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high‐risk HPV and cytology testing in a primary screening setting , 2005, International journal of cancer.
[12] M. J. Whitley,et al. Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring , 2004, Journal of medical virology.
[13] P. Coursaget,et al. Identification of Two Cross-Neutralizing Linear Epitopes within the L1 Major Capsid Protein of Human Papillomaviruses , 2002, Journal of Virology.
[14] B. Thomsen,et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study , 2002, BMJ : British Medical Journal.
[15] H. Toutenburg. Fleiss, J. L.: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York‐London‐Sydney‐Toronto 1973. XIII, 233 S. , 1974 .
[16] V. Fedorov,et al. Statistical approaches to establishing vaccine safety , 2002, Statistics in medicine.
[17] W. Quint,et al. Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.
[18] N. Christensen,et al. Immunological analyses of human papillomavirus capsids. , 2001, Vaccine.
[19] S. Napthine,et al. Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. , 1997, Virology.
[20] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[21] J. Fleiss. Statistical methods for rates and proportions , 1974 .
[22] S. Franceschi,et al. Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update , 2007, International journal of cancer.
[23] P. Coursaget,et al. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31 , 2006, Archives of Virology.